FDA Issued Warning to Houston Pharmacy Over GLP-1 Drugs
The federal agency raised concerns about the manufacturing and clinical oversight of compounded medications for local patients.
Updated on Sept. 22, 2026 in Diabetes
Live Poll
Do you trust the safety of compounded GLP-1 weight loss drugs compared to FDA-approved versions?
The FDA issued a warning letter to Houston-based Empower Pharmacy regarding the production and clinical justification of compounded GLP-1 drugs. The action follows findings from a November 2025 facility inspection.
Why it matters
The warning highlights regulatory scrutiny over whether compounded formulations of popular medications truly serve unique medical needs or bypass safety standards. This development underscores potential risks associated with rapidly produced, non-FDA-approved drug variations.
An FDA warning letter based on a November 2025 inspection identified significant concerns regarding the manufacturing practices of a pharmacy that dispensed nearly 3 million prescriptions during the first 10 months of 2024. The impact of the pharmacy's added B-vitamin formulations remains unverified.
The players
FDA
The federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
Empower Pharmacy
A Houston-based pharmacy facility that specializes in compounding medications, including GLP-1 receptor agonists.
The details
The FDA alleges that the pharmacy produces GLP-1 formulations, such as tirzepatide and semaglutide, that mirror approved drugs but contain added B vitamins. Investigators also noted that some telehealth-linked prescriptions rely on pre-generated justifications, calling into question the necessity of these compounded versions for individual patient care.
Timeline
2017 marked the issuance of the first warning letter to Empower Pharmacy.
January through October 2024 saw the pharmacy dispense nearly 3 million prescriptions.
November 2025 was the period when FDA inspectors conducted their facility evaluation.
September 18, 2026, is the date inscribed on the official FDA warning letter.
September 22, 2026, was the date the FDA publicly released the warning letter.
Health Landscape
This enforcement action highlights the ongoing regulatory tension regarding the FDA's regulatory framework for compounded drug formulations. It underscores a broader shift toward tighter oversight of facilities producing GLP-1 medications outside of standard commercial supply chains.
If you are currently taking a compounded GLP-1 medication, speak with your doctor to confirm that your prescription is sourced from a facility meeting all current safety requirements. Be cautious of telehealth platforms that automatically generate clinical justifications for these drugs without a thorough personal assessment.
The takeaway
The FDA’s warning emphasizes the importance of verifying the source and medical necessity of any compounded medication you receive. If you have questions about the safety or origin of your current prescription, discuss them directly with your prescribing physician.
Further reading
For more information on the management of chronic conditions, see our section on Diabetes.
Live Poll
Do you trust the safety of compounded GLP-1 weight loss drugs compared to FDA-approved versions?
